Pfizer‘s acquisition of Baxter’s authorized vaccines took place at the end of 2014, with Pfizer investing a total of USD 635 million (EUR 473 million). The Baxter production site in Orth an der Donau, which currently employs a workforce of 230 people to produce a vaccine against meningococcal C and FSME, was also part of the acquisition. The integration of the product portfolio purchased from Baxter International Inc. in December 2014 has now been concluded. Since May 1, 2015, Pfizer Austria has been the marketing authorization holder of the vaccines NeisVac-C(R) and FSME-IMMUN(R).
"With the plant in Austria, we have a clear commitment to the business location Austria“, says Robin Rumler, Managing Director of Pfizer Austria. As the marketing authorization holder, Pfizer is now in possession of complete responsibility for all authorization obligations, including activities in connection with pharmacovigilance, order management, sales and invoicing, inquiries on medical data and product complaints relating to the meningococcal C and FSME vaccines.